Developing Best-in-Class Radiopharmaceuticals for Cancer Patients

Rx for Biotech
19/09/2023 28 min
Developing Best-in-Class Radiopharmaceuticals for Cancer Patients

Listen "Developing Best-in-Class Radiopharmaceuticals for Cancer Patients"

Descargar episodio Ver en sitio original

Episode Synopsis

Our guests for this podcast episode are the co-founders of Ratio Therapeutics, CEO Jack Hoppin, PhD, and Chief Scientific Officer, John Babich, PhD.

Ratio Therapeutics's mission is to develop best-in-class radiopharmaceuticals for the treatment of cancers.

More episodes of the podcast Rx for Biotech

Restoring Breath: Biologic Innovation for the Most Vulenerable Patients 28/10/2025
Reprogramming Immunity: How CCR5 Blockade Could Redefine Cancer Therapy 14/10/2025
The Alpha Edge: Perspective Therapeutics on the Future of Theranostics and Radiopharmaceutical Therapies 09/09/2025
Harnessing the Immune System: PDS Biotech’s NextGen Approach to Cancer Treatment 21/08/2025
How Nonacus is Changing Cancer Detection with CEO, Jeff Bousfield 05/08/2025
Hope in Hard Places: A Potential New Option for Patients with Pancreatic Cancer 24/07/2025
How Mesenchymal Stem Cells Are Shaping the Future of Medicine with Dr. Kilian Kelly 03/06/2025
Patient Perspective with CAR-T Cell Therapy Advocate, Brad Watt 08/05/2025
How AI is Transforming Job Search and Recruiting in Life Sciences and Technology 24/04/2025
From Nigeria to the USA: Gene Therapy Journey with Sickle Cell Warrior, Jimi Olaghere 24/03/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA